Molina Healthcare, Inc.

Equities

MOH

US60855R1005

Managed Healthcare

Market Closed - Nyse 04:00:01 2024-04-15 pm EDT 5-day change 1st Jan Change
360.8 USD -4.17% Intraday chart for Molina Healthcare, Inc. -5.43% -0.13%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Molina Healthcare Shares Down After Price Target Cuts MT
Wells Fargo Cuts Price Target on Molina Healthcare to $410 From $440, Keeps Equalweight Rating MT
Truist Securities Adjusts Price Target on Molina Healthcare to $440 From $460 MT
Molina Healthcare Selected for Medicaid Service Contract in Michigan MT
All eyes on Powell Our Logo
BofA Securities Downgrades Molina Healthcare to Underperform From Neutral Reflecting Lower Risk-Reward, Price Target is $439 MT
Molina Healthcare Receives a Shareholder Proposal from John Chevedden CI
Wells Fargo Raises Price Target on Molina Healthcare to $440 From $420, Maintains Equal-Weight Rating MT
Molina Healthcare Insider Sold Shares Worth $401,050, According to a Recent SEC Filing MT
Truist Adjusts Price Target on Molina Healthcare to $460 From $435, Maintains Buy Rating MT
Molina Healthcare Insider Sold Shares Worth $597,570, According to a Recent SEC Filing MT
Molina Healthcare Insider Sold Shares Worth $299,340, According to a Recent SEC Filing MT
Wells Fargo Upgrades Molina Healthcare to Equalweight From Underweight, Adjusts Price Target $420 From $367 MT
Molina Healthcare Insider Sold Shares Worth $5,798,455, According to a Recent SEC Filing MT
UBS Adjusts Molina Healthcare Price Target to $395 From $380, Maintains Neutral Rating MT
Cantor Fitzgerald Adjusts Price Target on Molina Healthcare to $406 From $374, Maintains Overweight Rating MT
Deutsche Bank Adjusts Molina Healthcare Price Target to $357 From $375, Maintains Hold Rating MT
Transcript : Molina Healthcare, Inc., Q4 2023 Earnings Call, Feb 08, 2024
Molina Healthcare beats Q4 profit estimates on higher premiums RE
Molina Healthcare Q4 Adjusted Earnings, Revenue Increase; Issues 2024 Outlook MT
Earnings Flash (MOH) MOLINA HEALTHCARE Posts Q4 Revenue $9.05B, vs. Street Est of $8.38B MT
Earnings Flash (MOH) MOLINA HEALTHCARE Reports Q4 EPS $4.38, vs. Street Est of $4.35 MT
(MOH) MOLINA HEALTHCARE Expects Fiscal Year 2024 EPS $23.50 MT
(MOH) MOLINA HEALTHCARE Sees Fiscal Year 2024 Revenue $39.6B MT
Molina Healthcare, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Chart Molina Healthcare, Inc.
More charts
Molina Healthcare, Inc. specializes in the provision of health care services managed within the Medicaid and Medicare health insurance and coverage programs, and through the health insurance marketplace, financed by the States and the Federal Government of the United States. Revenues break down by activity as follows: - Health care services within the Medicaid program (80.9%): services for low-income individuals, families and people with disabilities; - health care services within the Medicare program (12.9%): services for the elderly and people with certain diseases, covered by the Medicare health insurance program; - operating a health insurance marketplace (6.2%; Marketplace): a platform for offering health insurance plans, and allowing members of the Medicaid program, whose rising incomes have taken them out of eligibility, to purchase federally subsidized health insurance policies. The group also offers virtual care services. At the end of 2023, Molina Healthcare, Inc. had approximately 5 million members broken down by program between Medicaid (4.5 million members), Medicare (0.2 million) and Marketplace (0.5 million). All revenues are earned in the United States.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
360.8 USD
Average target price
420.3 USD
Spread / Average Target
+16.49%
Consensus
  1. Stock Market
  2. Equities
  3. MOH Stock
  4. News Molina Healthcare, Inc.
  5. BofA Securities Double Downgrades Molina Healthcare to Underperform From Buy, Adjusts Price Target to $335 From $355